Reduction of GLP-1 receptor agonist activity has been shown to exert multiple anti-inflammatory effects in conditions like diabetes, neurodegenerative diseases, as Parkinson’s disease, and inflammatory bowel diseases [38]. The gene discussed is GLP1R; the disease is neurodegenerative disease.